Paper Details

  1. Home
  2. Paper Details

Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial.

Author: , AboulkerJean-Pierre, EspositoSusanna, HeathPaul T, LutsarIrja, MetsvahtTuuli, OeserClarissa, StandingJoseph, TrafojerUrsula M T, de CabreVincent Meiffredy

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study is comparing the efficacy of meropenem with a predefined standard of care (ampicillin + gentamicin or cefotaxime + gentamicin) in the treatment of late-onset neonatal sepsis (LOS) in 550 neonates and infants less than 90 days old. The primary endpoint is clinical response at 2 days after the end of study therapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Late onset neonatal sepsis (LOS) with the mortality of 17 to 27% is still a serious disease. Meropenem is an antibiotic with wide antibacterial coverage. The advantage of it over standard of care could be its wider antibacterial coverage and thus the use of mono-instead of combination th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193806/

データ提供：米国国立医学図書館（NLM）

Meropenem vs. Standard of Care for Late Onset Sepsis in Infants: A Randomized Controlled Trial Protocol

Late onset neonatal sepsis (LOS) remains a significant health concern, often leading to serious complications. This study aims to compare the effectiveness of meropenem, a broad-spectrum antibiotic, with a predefined standard of care for treating LOS in infants. The researchers will conduct a randomized controlled trial involving 550 infants with LOS, comparing meropenem to ampicillin + gentamicin or cefotaxime + gentamicin.

A Comparative Study of Meropenem and Standard of Care

This trial aims to determine whether meropenem offers a significant advantage over standard of care in treating LOS. The primary outcome will be the success rate of treatment, measured by factors like resolution of symptoms, eradication of microorganisms, and duration of antibiotic therapy. The trial will also assess secondary outcomes, including survival rates, relapse rates, and the impact of treatment on antibiotic resistance.

Navigating Sepsis Treatment in Infants

This trial represents a significant step forward in the understanding of [LOS] and the potential benefits of meropenem. While the results of the trial are eagerly awaited, it is essential to remember that [each infant is unique]. The best treatment approach for an individual infant will depend on factors such as [age, underlying conditions, and severity of infection].

Dr. Camel's Conclusion

This research signifies a crucial step towards improving the management of [LOS] in infants. Just as a camel navigates the desert with resilience and strength, healthcare professionals must be steadfast in their efforts to combat this challenging condition. This trial holds the potential to provide valuable insights into the effectiveness of meropenem, guiding future treatment strategies and improving outcomes for infants with LOS.

Date :
  1. Date Completed 2012-02-02
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21958494

DOI: Digital Object Identifier

PMC3193806

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.